Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
We are continuing to edit the extensive videos from our 8th annual live patient forum, to make them available for our community!
During this event, leading thoracic oncologists from around the world, as well as lung cancer patients who are active within the patient advocacy community, discussed subjects relevant to all targets as well as breakout sessions on rare mutations.
This 6-hour live virtual webinar was an opportunity for lung cancer patients and caregivers to hear from experts and participate in live virtual question and answer sessions. The forum offered panel discussions, live Q&A sessions, and breakout sessions focused on rare mutations such as EGFR, ALK, ROS, RET, and KRAS.
For videos from the full event, see https://cancergrace.org/video-collection/targeted-therapies-patient-forum-english. You can also see the edited videos on our YouTube Channel at https://youtube.com/playlist?list=PLWsyUmdjLXhHeJbIe-G4TU_0zA7TZ608Z.
View these links for the complete AGENDA and FACULTY information.

#Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: